Want to see KR:950210 full AI Analyst Report?
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh (950210) Revenue
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Revenue
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh had a revenue of 15.36B in the quarter ending Jun 30, 2025, with 2848.75%. This bring the company's revenue in the last twelve months to 26.06B, Increased 60.72%. In the fiscal year ending Jun 30, 2025, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh had annual revenue of 26.06B with 82.14% growth.
- Revenue (ttm)
- 26.06B
- Revenue Growth
- 84.72%
- P/S Ratio
- 9.27
- Revenue/Employee
- KRW 407,250,719
- Employees
- 64
- Market Cap
- KRW 241.59B
Revenue Chart
Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh Revenue - Annual
Revenue History
| Fiscal End Date | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 26.06B | 11.75B | 82.14% |
| Jun 30, 2025 | 14.31B | 13.62B | 1976.67% |
| Jun 30, 2023 | 689.08M | 527.23M | 325.77% |
| Jun 30, 2022 | 161.84M | 161.84M | ― |
| Jun 30, 2022 | 0.00 | 0.00 | ― |
| Jun 30, 2021 | 0.00 | 0.00 | ― |
| Jun 30, 2020 | 0.00 | -2.09B | -100.00% |
| Jun 30, 2019 | 2.09B | 2.09B | ― |
| Jun 30, 2018 | 0.00 | ― | ― |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.